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Abstract
Prophylaxis is considered optimal care for hemophilia patients to prevent bleeding and to preserve joint function
thereby improving quality of life (QoL). The evidence for prophylaxis is irrefutable and is the standard of care in
developed nations. Prophylaxis can be further individualized to improve outcomes and cost effectiveness.
Individualization is best accomplished taking into account the bleeding phenotype, physical activity/lifestyle, joint
status, and pharmacokinetic handling of specific clotting factor concentrates, all of which vary among individuals.
Patient acceptance should also be considered. Assessment tools (e.g. joint status imaging and function studies/
scores, QoL) for determining and monitoring risk factors and outcome, as well as population PK profiling have been
developed to assist the individualization process. The determinants of optimal prophylaxis include (1) factor dose/
dosing frequency, hence, cost/affordability (2) bleeding triggers (physical activity/lifestyle, chronic arthropathy and
synovitis) and (3) bleeding rates. Altering one determinant results in adjustment of the other two. Thus, the trough
level to protect from spontaneous bleeding can be increased in patients who have greater bleeding risks; and
prophylaxis to achieve zero joint bleeds is achievable through optimal individualization. Prophylaxis in economically
constrained nations is limited by the ill-affordability of clotting factor concentrates. However, at least 5 studies on
children and adults from Thailand, China and India have shown superiority of low dose (~5–10 IU kg−1 2-3× per
week) prophylaxis over episodic treatment in terms of bleed reduction, and quality of life, with improved physical
activity, independent functioning, school attendance and community participation. In these nations, the prophylaxis
goals should be for improved QoL rather than “zero bleeds” and perfect joints. Prophylaxis can still be
individualized to affordability. Higher protective trough level can be achieved by using smaller doses given more
frequently without an increase in consumption/cost. The bleeding trigger can also be down-regulated by avoiding
unnecessary injury, and by engaging in judicious strengthening exercises appropriate to the joint status to improve
balance and joint stabilization. Central to the success of prophylaxis are clinics with comprehensive care that
provide the necessary professional expertise, support, and counseling, to educate patients, families, and other
healthcare professionals, and to support research for improved hemophilia care.
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Background
Individualized prophylaxis has become an important
topic in how prophylaxis can be optimized based on
various patient factors such as bleeding risk, pharma-
cokinetic (PK) profile, joint status and physical activ-
ity/lifestyle. With the understanding of interpatient
heterogeneity influencing these factors, individualized
prophylaxis should be the ideal strategy to optimize
factor utilization while improving patient quality of
life (QoL) and joint health. In developed nations
where there are fewer constraints in terms of factor
affordability, the ultimate goal of “zero bleeds” and
possibly perfect joints is achievable with the right
peak and trough levels adjusted for individual risk
factors and PK handling. Assessment tools (e.g. MRI/
ultrasound imaging for joint status, QoL tools, joint
scores) for determining and monitoring risk factors
and outcome, as well as population PK profiling have
been developed to assist us in this individualization
process. Although prophylaxis in general is expensive,
and the proposed tools to assist with individualization
are time consuming and resource intensive, the over-
all economic savings from improved QoL with almost
no bleeding and bleed-related complications, should
be more than enough to offset the costs of its imple-
mentation in resource adequate nations. The question
is whether it is possible for the developing world to
practice individualized prophylaxis when there are
barely enough resources and affordable factor concen-
trate to ensure all bleeds are treated adequately or
even treated at all. Approximately 75–80 % of the
world’s hemophilia population lives in developing na-
tions and we are at risk of leaving this large propor-
tion of patients behind and undertreated if we
assume the goal for prophylaxis should always be
“zero bleeds”. Prophylaxis regimens that focus on
using resource intensive measurement tools, and PK
profiling models may not be attainable to all. How-
ever, this does not mean developing nations should
not strive to achieve some form of prophylaxis in the
interim. Simply the goals of prophylaxis need to be
adjusted such that it is individualized for QoL rather
than “zero bleeds”, for independent function and
gainful employment rather than pristine joints, and
for trough levels that minimize bleed events rather
than PK profiling to ensure a certain pre-defined
trough level. For resource-limited countries, prophy-
laxis must be individualized to include affordability as
a major determinant in order to optimize low-dose
regimens that have demonstrated superiority com-
pared to episodic treatment. This review aims to
communicate the current concepts of individualized
prophylaxis and how this might be adapted and ap-
plied in both developed and developing nations.
Review
The evolution of prophylaxis
Prophylaxis is considered optimal care for hemophilia
patients to prevent bleeding and to preserve joint func-
tion [1]. The original idea being that keeping factor
levels above 1 % converts severe hemophilia to a moder-
ate severity phenotype where spontaneous joint bleeds
and chronic arthropathy is less frequently observed. The
Swedish have been practicing prophylaxis in young boys
since the 1960’s and demonstrated continuous prophy-
laxis started at an early age to prevent factor levels from
falling below 1 %, preserved joint function, and allowed
patients to lead normal lives [2]. The superiority of pri-
mary prophylaxis (for definition, see Table 1) compared
to episodic treatment is no longer questioned based on
pivotal randomized controlled studies [3, 4]. Studies of
secondary and tertiary prophylaxis in adolescents and
adults have also shown benefit in reducing annual bleed-
ing rate (ABR), rate of joint deterioration, and number
of days lost from school or work compared to episodic
treatment [5–7] With this irrefutable evidence, prophy-
laxis (over episodic treatment) should be the standard of
care to all severe hemophilia individuals.
However, practical issues related to the cost and bur-
den of prophylaxis, together with the recognized hetero-
geneity in bleeding risk and PK handling of factor
concentrates, have lead us to question what the ideal
prophylaxis regimen for severe hemophilia should be.
High-dose (Malmö) prophylaxis regimen is considered
“gold standard” [2]. Unfortunately, the costs associated
with such a regimen and patient acceptance of frequent
infusions starting at a very young age has been prohibi-
tive for its widespread implementation. Alternatively,
intermediate-dose prophylaxis has been used by the
Dutch since 1968 (Table 2) [8]. A long-term outcome
study that compared the high-dose Malmö to the
intermediate-dose Dutch prophylaxis showed compar-
able QoL (EQ-5D 0.84 vs 1.0), despite a small but sig-
nificant reduction in median annual joint bleeding rate
(AJBR, 1.3 vs. 0) and hemophilia joint health score
(HJHS, 9 vs 4) [8]. However, annual factor consumption
was 2150 IU kg−1 per year lower for the Dutch regimen
resulting in a sizeable cost difference (US$159,000 based
on US$1.10 per unit [8]) that argued against cost-







Primary ≤1 ≤3 absent
Secondary ≥2 any absent
Tertiary ≥2 any present
All refer to continuous prophylaxis intended for 52 weeks per year, and taken
for at least 45 weeks of the year under consideration
*large joints = knees, ankles, elbows, hips, shouders
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effectiveness for quality-adjusted life years (QALY) for
high-dose prophylaxis.
The Canadian Hemophilia Primary Prophylaxis Study
(CHPS) looked at reduced-intensity escalating dose
prophylaxis (Table 2) [9]. The impetus for this regimen
followed observations that about 10–15 % of severe
hemophilia patients have infrequent bleeding and
hemarthroses, and little or no joint damage [10]. The
CHPS study aimed to tailor the prophylaxis regimen to
balance the burden of IV injections, need for central
venous catheter (CVC) insertions, and the costs of factor
concentrate, against the level of arthropathy and pa-
tient’s QoL. In this study, patients were able to preserve
reasonable joint function with a mean AJBR of 0.78. At
15 years follow up 9 % of subjects remained on step one
(50 IU/ kg−1 once weekly prophylaxis) and 32 % on step
two (30 IU kg−1 twice weekly) [9]). The mean annual
factor consumption was 3228 IU kg−1 per year, less than
the ~ 6000 IU kg−1 per year for full-dose alternate day
regimen [11]. In addition only 30 % of subjects in CHPS
required CVCs compared to 82 % from a survey of
North American centres of children on full-dose prophy-
laxis [12]. A cost-utility analysis using Markov modelling
taking into account costs of factor, medical resources, ef-
fectiveness and health-related QoL (HR-QoL) showed
the QALY for full-dose and escalating dose (CHPS)
prophylaxis were the same due to the trade-off in greater
number of CVCs needed for full-dose and the higher
number of bleeds with escalating dose prophylaxis.
However, the incremental cost per QALY gained with
full-dose was > CAD$1,000,000, suggesting escalating
dose prophylaxis is the greater cost-saving strategy of
the two regimens [13].
The shift in paradigm: individualized prophylaxis
CHPS was a pioneer in tailoring prophylaxis and was
able to produce adequate preservation of joint status
using less factor with some cost saving. However, CHPS
takes into account only one aspect of bleeding risk,
bleed frequency, and its applicability is limited to
pediatric patients initiating primary prophylaxis. Indi-
vidualizing prophylaxis that is applicable to all age
groups should take into consideration additional factors
that contribute to bleeding risk such as level of physical
activity/lifestyle, existing joint arthropathy, chronic
synovitis, and time spent below an acceptable trough
level, as well as patient’s acceptability, burden of fre-
quent venipunctures and venous access issues especially
in children, and ability to self-guided care. The intrinsic
half-life of a factor concentrate and the variation in pa-
tient PK handling influences the strategies for individual-
izing prophylaxis. This has generated intense interest in
measuring an individual’s PK profile, particularly elimin-
ation half-life of factor concentrates for an individual pa-
tient. Full PK profiling requires measuring multiple time
points following factor infusion to generate an accurate
estimate of elimination half-life. To circumvent the in-
convenience of multiple venipunctures, population PK
models have been developed for various factor concen-
trates to predict individual PK parameters with only 2 or
3 time points. Understanding a patient’s PK profile al-
lows tailoring a prophylaxis regimen to a dose and inter-
val that achieves a predetermined optimal trough level
that will minimize bleeding and maximize cost effective-
ness for that particular patient.
What target trough level should be used has been an
issue of debate. It is widely accepted that keeping trough
levels above 1 % should be a minimum as few joint
bleeds occur above this level. However, there is emerging
evidence to suggest that maybe 1 % is not sufficient and
that targeting higher trough levels should be pursued to
maintain the healthiest joints possible. Epidemiologic
evaluation on a Dutch cohort at diagnosis demonstrates
that a FVIII level at 1 % may still have upwards of 5 joint
bleeds per year, while levels >10–12 % have essentially
zero joint bleeds [14]. It has been argued that even one
bleed into the healthy joint of a growing child is one too
many [15]. Canine studies demonstrate that a single
joint bleed produces enough inflammation to cause per-
manent damage to developing cartilage. It is possible
that the same in a maturing human joint may have dele-
terious effects as the individual ages [16]. We currently
have limited long term data on primary prophylaxis regi-
mens with the most mature data coming from the
Swedish versus Dutch prophylaxis study that supports
the idea that higher troughs achieve the healthiest joints
due to near zero AJBR [8]. Additionally the US joint out-
come study showed MRI-detectable joint damage still
occurred in individuals who had no clinically evident
joint bleeding [4]. Presumably, this resulted from




25–40 IU kg−1 3 times a week or every other days starting at age 1–2 years, irrespective of bleeding history
Intermediate-dose
(Dutch) [8]
15–25 IU kg−1 2–3 times per week, usually started after ≥1 hemarthrosis
Escalating-dose
(Canadian) [9]
50 IU kg−1 once a week, with dose increased to 30 IU kg−1 twice a week, then 25 IU kg−1 every other day,
in response to bleeding frequency
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subclinical joint bleeds which theoretically may be
averted by a prophylaxis regimen that maintained higher
trough levels.
Determinants of individualized prophylaxis
In a recent review on optimizing prophylaxis [17],
Oldenburg proposed 3 main determinants for prophy-
laxis (Fig. 1): (1) a target trough level dictated by dose
and interval of prophylaxis based on patient PK parame-
ters and the availability and cost of factor concentrate,
(2) the bleeding triggers which includes degree of phys-
ical activity/lifestyle, presence and severity of joint ar-
thropathy and chronic synovitis, and (3) the number of
bleeds, specifically joint bleeds, that are deemed accept-
able (Fig. 1). These 3 factors form a dynamic triangle for
optimizing prophylaxis. When 1 determinant is changed,
the other 2 will adjust. For example, in the setting of un-
limited resources “zero bleeds” and normal or even in-
tense physical activity is achievable by using high dose,
frequent injections to target higher troughs (5–10 % or
more). At the centre, patient acceptance and ability to
self-guided care will play a role in how much weight can
be placed on each corner of this triangle.
In the developed world where affordability of factor is
not a major constraint, determinant (1), has a propor-
tionally greater influence on the triangle since the trough
level is the determinant we have the greatest control
over. For determinant (2), bleeding triggers such as de-
gree of arthropathy, presence of chronic synovitis, are in-
herent to the individual and cannot be easily changed.
However, physical activity/lifestyle can be adapted to the
degree of arthropathy, and the leeway to intensify physical
activity is driven by trough level and number/intensity of
peaks that determinant (1) can afford. Determinant (3),
number of bleeds, is then a direct consequence of mostly
how much determinant (1) can be changed. Therefore, in
the developed world prophylaxis regimens should be
adjusted to achieve the lowest number of bleeds pos-
sible. Given that the terminal half-life has the greatest
impact on the trough, simply shortening the interval
between infusions, even by 24 h, will cumulatively in-
crease the trough level. Recent introduction of ex-
tended half-life products will provide patients with
more options on frequency of infusion for a desired
trough level.
Prophylaxis in resource limited nations: using low-dose
and how it can still be individualized
The determinants of prophylaxis remain the same for
developing nations, however; the freedom to adjust the
determinants is impaired by lack of resources and af-
fordable product. Thus, the majority of patients in devel-
oping countries continue to receive episodic treatment
rather than prophylaxis. Full dose, and even intermediate
dose prophylaxis is clearly not affordable/possible. Thus,
adjusting trough levels to achieve a predefined target
may become a moot point in the prophylaxis triangle.
Without prophylaxis, these patients suffer tremendous
disability, leaving them with crippling arthropathy, and
unable to integrate fully to society. Many become wheel-
chair bound, unable to attend school or secure gainful
employment.
It seems unacceptable to deny 75–80 % of the world’s
hemophilia population of prophylaxis when the benefits
of this treatment are so clear. However, studies from
Thailand, China and India are providing evidence that
even low-dose prophylaxis can have major impact on
number of bleeds, QoL, and functional participation in
society. Four pediatric pilot studies, 3 from Thailand and
China, and a small randomized study from India, used
low-dose prophylaxis 8–10 IU kg−1 twice a week. Even
though the numbers were small and the follow up
≤1 year, these studies demonstrate significant reductions
in ABRs, AJBRs, fewer days absenteeism from school,
and improved QoL despite only 37 % of children in the
Fig. 1 Determinants of prophylaxis. Prophylaxis treatment regimen
has 3 main determinants: (1) the given resources/concentrate
availability/afffordability to target a specific trough level and/or
dosage/intervals of infusions, all of which reflect the consumptions/
costs; (2) the bleeding trigger, which comprises physical activity/
lifestyle, presence and degree of arthropathy, and presence of
chronic synovitis; and (3) the number of bleeds, especially joint
bleeds, that are regarded as acceptable. These 3 determinants form
a triangle. If 1 determinant is changed, the other 2 will adjust.
Central to these, patient acceptability and ability to self-guided care
must also be considered. With unlimited resources, “zero bleeds”
and normal physical activity may be targeted. With few resources,
only low-dose substitutions may be given, thus accepting a certain
number of bleeds and limited physical activity. None-the-less where
acceptable to the patient with adequate venous access, increasing
frequency of infusion will attain a higher trough level with a lower
dose (and hence consumptions/costs, see Fig. 2). Determinant 2 can
also be improved by avoiding injury and by improving muscle
strength and balance with exercise appropriate to the patients’ joint
status. (Adapted from Oldenburg [17], with permission)
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Indian study had measured trough levels ≥1 % [18–21].
Factor consumption with prophylaxis was higher com-
pared to on demand (1050 vs 675 IU kg−1 per year) in
the Indian study [21] but is significantly lower when
compared to full dose (~6000 IU kg−1 per year) [11] and
escalating dose (~3228 IU kg−1 per year) [9] prophylaxis.
Only one study has looked at low-dose tertiary
prophylaxis in adult patients who at baseline already
have established severe arthropathy. This Chinese study
used 5–10 IU kg−1 2–3 times per week depending on
what the patient can afford, and demonstrated a 77 % re-
duction in ABR and significant improvement in
functional independence scores (FISH) [22]. Although
there was no measurable structural improvement (un-
changed radiologic joint scores), some of the wheelchair-
bound patients were able to walk on their own again,
highlighting the significant impact low-dose prophylaxis
made. Although solid evidence from large clinical trials
on the benefits of low-dose prophylaxis is still lacking, it
appears to be a feasible way to deliver prophylaxis treat-
ment in resource-limited nations; at least until higher
dose prophylaxis becomes economically possible.
As use of low-dose prophylaxis begins to gain support
and is implemented in other resource-limited countries;
a
b
Fig. 2 Low dose prophylaxis in economically constrained environment: Influence of FVIII infusion frequency on trough level and factor
consumption. (Modeled based on an average FVIII recovery of 2 IU dL−1 per IU kg−1 infused and a T1/2 of 12 h). a A dosage of 10 IU kg
−1 two-
times a week as well as 5 IU kg−1 three-times a week (weekly consumption 20 and 15 IU kg−1 per week respectively) each results in a trough level
<1 IU dL−1 in 3–4 of the 7 days in the week (but with trough levels always higher with three-times a week than with two-times a week prophylaxis
even at lower dose with lower consumption), whereas as little as 2 IU kg−1 daily (qd, weekly consumption 14 IU kg−1 per week) produces daily trough
of ~1.33 IU dL−1. [For three-times weekly prophylaxis, doubling the infusion dose from 5 to 10 IU kg−1 will double the day 2, 4 and 6 trough levels to
~1.33 IU dL−1, but still leave trough level on day 7 at 0.66 IU dL−1 (i.e. <1 IU dL−1, figure not shown)]. Prophylaxis at 10 IU kg−1 every-two-day (q2d) is
shown in Fig. 2b. b In order for an every-three-day (q3d) regimen to produce a trough level similar to that obtained by every-two-day (q2d) infusion
(e.g.1.33 IU/dL), the dosage per infusion has to be increased, whereas daily infusion requires a lower per infusion dosage. Compared to the q2d
regimen, factor consumption is 2.8× more for the q3d regimen but 2.5× less for the qd regimen. These relative consumption multiples are the same
for other target trough levels and other PK handling of clotting factors for a particular individual. (Figures not drawn to scale. Peak and trough levels
will be different for different patients depending on their individual pharmacokinetic handling of the particular clotting factor, but the principles
remain the same. Peak and trough levels tend to increase slightly with infusions but remain more or less constant after the first few infusions and
steady state is achieved. Values for peak levels represent value range during steady state with each regimen)
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we believe that the principles of individualization can
still be used to optimize prophylaxis for any given pa-
tient within their fiscal limitations to maximize benefits.
By determining how much factor a patient can afford
over a given period of time, much more effective
prophylaxis with higher trough levels can be achieved
for that individual by giving smaller doses more fre-
quently (Fig. 2). Figure 2a shows how increasing dose
frequency can improve troughs without increasing con-
sumption or costs. Assuming an average FVIII recovery
of 2 IU dL−1 per IU kg−1 infused and a T1/2 of 12 h, a
dosage of 10 IU kg−1 two-times a week or 5 IU kg−1
three-times a week (weekly consumption 20 and
15 IU kg−1 per week respectively) each results in a
trough level <1 IU dL−1 in 3–4 out of the 7 days per
week, whereas as little as 2 IU kg−1 daily (qd, weekly
consumption 14 IU kg−1 per week) produces daily
troughs of ~1.33 IU dL−1. This is an example of adjust-
ing determinant (1) to individualize prophylaxis based
on affordability in environments of resource constraint.
This is particularly important for older children and
adults with higher weight (hence, total dose) but have
good veins for more frequent infusion. Conversely, to
maintain any given trough level (e.g. 1.33 IU dL−1), clot-
ting factor consumption per week is decreased by ~2.5×
when given daily, and increased by ~2.8× when given
every 3rd day in comparison to “standard” every-other-
day prophylaxis (Fig. 2b).
In order for prophylaxis to work in developing nations,
there must be a clinic where by injections are given or
patients are taught to self-inject (home care), and educa-
tion for self-care and prophylaxis acceptance/adherence
can be provided. Clinic support is also needed to educate
patients on appropriate physical activity and life style ad-
justment, bleeding triggers that can be controlled.
Hemophilia patients in developing nations often shy
away from exercising because of the fear of bleeding.
However, proper education on preventing avoidable in-
juries (including use of protective gear) and exercises
that are appropriate to their joint status and degree of
arthropathy requires professional help from trained-
physiotherapists and physicians. Exercises to improve
muscle strength and balance help stabilize joints and can
avert joint bleeds in patients who are less protected on
low dose prophylaxis. A dedicated hemophilia clinic with
comprehensive care remains fundamental to prophylaxis
irrespective of economic capacity, and should also be the
priority in all developing nations.
Conclusion
Prophylaxis has significantly changed the lives of many
hemophilia patients. Those living in developed nations
have already benefited from prophylaxis, but room re-
mains for improvement. Individualized prophylaxis by
understanding bleeding triggers and PK profiles would
allow us to target appropriate trough levels that can
achieve “zero bleeds”, provide the greatest chance of pre-
serving joint health, and ultimately meet the specific
goals for each patient. Although prophylaxis is expen-
sive, this is not a reason for developing nations to re-
main complacent with inferior episodic treatment. Low
and very-low dose prophylaxis and individualizing it to
what is affordable for a given patient or nation, may
bridge this gap created by global economic disparity.
Greater efforts must be made in establishing compre-
hensive care and home care in developing nations in
order for any type of prophylaxis to be successful. And
finally maximizing the amount of time spent per week
above target by using small but frequent doses of factor
within one’s fiscal constraints may individualize prophy-
laxis treatment for greater returns in functional inde-
pendence and quality of life.
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